Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity

• Main Authors: Hyun-Woong Cho, Sanghoon Lee, Kyung-Jin Min, Jin Hwa Hong, Jae Yun Song, Jae Kwan Lee, Nak Woo Lee, Tak Kim
• Format: Article
• Language: English
• Published: MDPI AG 2020-10-01
• Series: International Journal of Molecular Sciences
• Subjects: gonadotoxicity; fertility preservation; embryo cryopreservation; oocyte cryopreservation; ovarian tissue cryopreservation; oocyte in vitro maturation
• Online Access: https://www.mdpi.com/1422-0067/21/20/7792

Due to improvements in chemotherapeutic agents, cancer treatment efficacy and cancer patient survival rates have greatly improved, but unfortunately gonadal damage remains a major complication. Gonadotoxic chemotherapy, including alkylating agents during reproductive age, can lead to iatrogenic premature ovarian insufficiency (POI), and loss of fertility. In recent years, the demand for fertility preservation has increased dramatically among female cancer patients. Currently, embryo and oocyte cryopreservation are the only established options for fertility preservation in women. However, there is growing evidence for other experimental techniques including ovarian tissue cryopreservation, oocyte in vitro maturation, artificial ovaries, stem cell technologies, and ovarian suppression. To prevent fertility loss in women with cancer, individualized fertility preservation options including established and experimental techniques that take into consideration the patient’s age, marital status, chemotherapy regimen, and the possibility of treatment delay should be provided. In addition, effective multidisciplinary oncofertility strategies that involve a highly skilled and experienced oncofertility team consisting of medical oncologists, gynecologists, reproductive biologists, surgical oncologists, patient care coordinators, and research scientists are necessary to provide cancer patients with high-quality care.